Oncology Venture ready for turning Novartis candidate into precision medicine
Danish biotech firm Oncology Venture has fine-tuned its DRP technology to become better at predicting which patients will benefit from treatment with Novartis' candidate dovitinib against cancer in the kidneys and uterus.
Danish Oncology Venture has turned its attention to the cancer candidate dovitinib, which was acquired from Swiss drug group Novartis and already showed good results in a phase III trial, writes the company in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
